Compugen Ltd. (CGEN)
(Delayed Data from NSDQ)
$8.96 USD
-1.40 (-13.51%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
D Value B Growth A Momentum B VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?
by Zacks Equity Research
On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.
PFEPositive Net Change ALNYNegative Net Change CGENNegative Net Change BNTXNegative Net Change
biotechs
Insight Enterprises' (NSIT) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Insight Enterprises' (NSIT) Q3 performance benefits from acquisition of PCM amid sluggish demand from Asia Pacific and EMEA.
FLSNegative Net Change HBINegative Net Change NSITNegative Net Change CGENNegative Net Change
earnings tech-stocks
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
LLYNegative Net Change ALNYNegative Net Change AVEONegative Net Change CGENNegative Net Change
biotechs
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
ALNYNegative Net Change VRTXNegative Net Change ADMANegative Net Change CGENNegative Net Change
biotechs
What's in Store for Selecta (SELB) This Earnings Season?
by Zacks Equity Research
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
ALNYNegative Net Change SRPTPositive Net Change CGENNegative Net Change SELBPositive Net Change
biotechs
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
GILDNegative Net Change ALNYNegative Net Change VRTXNegative Net Change CGENNegative Net Change
biotechs
Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.
CGENNegative Net Change
medical
How Compugen (CGEN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CGENNegative Net Change
medical
Top Ranked Momentum Stocks to Buy for May 8th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 8th.
GNMKNegative Net Change CHGGNegative Net Change CGENNegative Net Change
internet medical
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
CGENNegative Net Change
momentum-investor momentum-stocks price-change volume
What Makes Compugen (CGEN) a New Strong Buy Stock
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CGENNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Top Ranked Momentum Stocks to Buy for April 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.
KPTINegative Net Change CGENNegative Net Change AUNegative Net Change
gold medical
Company News for Mar 10, 2020
by Zacks Equity Research
Companies In The News Are: COCP, CGEN, AAPL, NINE
AAPLNegative Net Change CGENNegative Net Change NINENegative Net Change COCPNegative Net Change
computers medical
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
BMYNegative Net Change MDCOPositive Net Change CGENNegative Net Change QURENegative Net Change EPZMNegative Net Change ACADNegative Net Change CUENegative Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
CGENNegative Net Change EPZMNegative Net Change ACADNegative Net Change CUENegative Net Change KRYSNegative Net Change
biotechs
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
EPZMNegative Net Change CGENNegative Net Change ACADNegative Net Change KRYSNegative Net Change CUENegative Net Change
biotechs pharmaceuticals
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
CGENNegative Net Change
momentum-investor momentum-stocks price-change volume
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CGENNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
by Zacks Equity Research
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
MYOKPositive Net Change CGENNegative Net Change ALDRPositive Net Change ALXNNegative Net Change
biotechs
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
by Zacks Equity Research
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
PFEPositive Net Change PRQRNegative Net Change CGENNegative Net Change VCNXNegative Net Change
biotechs
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
CGENNegative Net Change CLDXNegative Net Change PRQRNegative Net Change MNKPositive Net Change
medical
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
AMAGPositive Net Change CGENNegative Net Change BGNENegative Net Change GHNegative Net Change
biotechs earnings
Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CGENNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CGENNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook energy rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Compugen (CGEN) a New Strong Buy Stock
by Zacks Equity Research
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CGENNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank